Insights Into Ferroptosis: Targeting Glycolysis to Treat Graves’ Orbitopathy
Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO. We aimed to identify the divergent role of ferroptosis in the GO...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 107; no. 7; pp. 1994 - 2003 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
16.06.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-972X 1945-7197 1945-7197 |
DOI | 10.1210/clinem/dgac163 |
Cover
Loading…
Abstract | Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO.
We aimed to identify the divergent role of ferroptosis in the GO and control orbital fibroblasts (OFs).
Orbital fat/connective tissues and serum immunoglobulins (Igs) were collected from GO and control subjects. Cell viability and lipid peroxidation were measured to evaluate ferroptosis sensitivity. Pyruvate dehydrogenase kinase 2 (PDK2) level and oxygen consumption rate were quantified to assess glycolysis status.
Primary OFs were cultured from orbital tissues. Ferroptosis was induced by cystine deprivation and/or erastin treatment. The GO OFs possessed stronger resistance to ferroptosis than the control OFs. Selenium, a potential ferroptosis inhibitor, protected the control OFs from ferroptosis. Both transcriptomic and proteomic analyses indicated glycolytic shift in the GO OFs. Metabolic profiling, PDK2 quantification, and oxygen consumption assay confirmed enhanced glycolysis in the GO OFs. Inhibition of glycolysis by PDK2 knockdown and dichloroacetic acid (DCA) promoted ferroptosis sensitivity in the GO OFs. The ferroptosis-sensitizing effects of DCA were also observed when the GO OFs were treated with GO-Igs. IGF1R overexpression in the GO OFs contributed to glycolysis shift. IGF1R inhibitory antibodies facilitated ferroptosis induction in the GO OFs, but the effects were less remarkable under GO-Igs treatment.
These study findings establish that glycolysis facilitates ferroptosis resistance in the GO OFs, providing insights into the therapeutic role of glycolysis for GO treatment. |
---|---|
AbstractList | Context: Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO. Objective: We aimed to identify the divergent role of ferroptosis in the GO and control orbital fibroblasts (OFs). Methods: Orbital fat/connective tissues and serum immunoglobulins (Igs) were collected from GO and control subjects. Cell viability and lipid peroxidation were measured to evaluate ferroptosis sensitivity. Pyruvate dehydrogenase kinase 2 (PDK2) level and oxygen consumption rate were quantified to assess glycolysis status. Results: Primary OFs were cultured from orbital tissues. Ferroptosis was induced by cystine deprivation and/or erastin treatment. The GO OFs possessed stronger resistance to ferroptosis than the control OFs. Selenium, a potential ferroptosis inhibitor, protected the control OFs from ferroptosis. Both transcriptomic and proteomic analyses indicated glycolytic shift in the GO OFs. Metabolic profiling, PDK2 quantification, and oxygen consumption assay confirmed enhanced glycolysis in the GO OFs. Inhibition of glycolysis by PDK2 knockdown and dichloroacetic acid (DCA) promoted ferroptosis sensitivity in the GO OFs. The ferroptosis-sensitizing effects of DCA were also observed when the GO OFs were treated with GO-Igs. IGF1R overexpression in the GO OFs contributed to glycolysis shift. IGF1R inhibitory antibodies facilitated ferroptosis induction in the GO OFs, but the effects were less remarkable under GO-Igs treatment. Conclusion: These study findings establish that glycolysis facilitates ferroptosis resistance in the GO OFs, providing insights into the therapeutic role of glycolysis for GO treatment. Key Words: glycolysis, ferroptosis, cystine deprivation, orbital fibroblast, Graves' orbitopathy Abbreviations: 1H7, IGF1R inhibitory antibody 1H7; CCK-8, Cell Counting Kit-8; DCA, dichloroacetic acid; DMEM, Dulbecco's Modified Eagle Medium; FBS, fetal bovine serum; GD, Graves' disease; GO, Graves' ophthalmopathy; GPX4, glutathione peroxidase 4; IGF1, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes; OF, orbital fibroblast; OXPHOS, oxidative phosphorylation; PDK2, pyruvate dehydrogenase kinase 2; ROS, reactive oxygen species; SLC7A11, cystine-glutamate transporter; TCA, tricarboxylic acid (cycle); TMB, teprotumumab; TSHR, thyroid-stimulating hormone receptor; WES, Capillary Western Immunoassay Kit. Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO.CONTEXTOxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO.We aimed to identify the divergent role of ferroptosis in the GO and control orbital fibroblasts (OFs).OBJECTIVEWe aimed to identify the divergent role of ferroptosis in the GO and control orbital fibroblasts (OFs).Orbital fat/connective tissues and serum immunoglobulins (Igs) were collected from GO and control subjects. Cell viability and lipid peroxidation were measured to evaluate ferroptosis sensitivity. Pyruvate dehydrogenase kinase 2 (PDK2) level and oxygen consumption rate were quantified to assess glycolysis status.METHODSOrbital fat/connective tissues and serum immunoglobulins (Igs) were collected from GO and control subjects. Cell viability and lipid peroxidation were measured to evaluate ferroptosis sensitivity. Pyruvate dehydrogenase kinase 2 (PDK2) level and oxygen consumption rate were quantified to assess glycolysis status.Primary OFs were cultured from orbital tissues. Ferroptosis was induced by cystine deprivation and/or erastin treatment. The GO OFs possessed stronger resistance to ferroptosis than the control OFs. Selenium, a potential ferroptosis inhibitor, protected the control OFs from ferroptosis. Both transcriptomic and proteomic analyses indicated glycolytic shift in the GO OFs. Metabolic profiling, PDK2 quantification, and oxygen consumption assay confirmed enhanced glycolysis in the GO OFs. Inhibition of glycolysis by PDK2 knockdown and dichloroacetic acid (DCA) promoted ferroptosis sensitivity in the GO OFs. The ferroptosis-sensitizing effects of DCA were also observed when the GO OFs were treated with GO-Igs. IGF1R overexpression in the GO OFs contributed to glycolysis shift. IGF1R inhibitory antibodies facilitated ferroptosis induction in the GO OFs, but the effects were less remarkable under GO-Igs treatment.RESULTSPrimary OFs were cultured from orbital tissues. Ferroptosis was induced by cystine deprivation and/or erastin treatment. The GO OFs possessed stronger resistance to ferroptosis than the control OFs. Selenium, a potential ferroptosis inhibitor, protected the control OFs from ferroptosis. Both transcriptomic and proteomic analyses indicated glycolytic shift in the GO OFs. Metabolic profiling, PDK2 quantification, and oxygen consumption assay confirmed enhanced glycolysis in the GO OFs. Inhibition of glycolysis by PDK2 knockdown and dichloroacetic acid (DCA) promoted ferroptosis sensitivity in the GO OFs. The ferroptosis-sensitizing effects of DCA were also observed when the GO OFs were treated with GO-Igs. IGF1R overexpression in the GO OFs contributed to glycolysis shift. IGF1R inhibitory antibodies facilitated ferroptosis induction in the GO OFs, but the effects were less remarkable under GO-Igs treatment.These study findings establish that glycolysis facilitates ferroptosis resistance in the GO OFs, providing insights into the therapeutic role of glycolysis for GO treatment.CONCLUSIONThese study findings establish that glycolysis facilitates ferroptosis resistance in the GO OFs, providing insights into the therapeutic role of glycolysis for GO treatment. Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from lipid peroxidation. Little is known about the role of ferroptosis in GO. We aimed to identify the divergent role of ferroptosis in the GO and control orbital fibroblasts (OFs). Orbital fat/connective tissues and serum immunoglobulins (Igs) were collected from GO and control subjects. Cell viability and lipid peroxidation were measured to evaluate ferroptosis sensitivity. Pyruvate dehydrogenase kinase 2 (PDK2) level and oxygen consumption rate were quantified to assess glycolysis status. Primary OFs were cultured from orbital tissues. Ferroptosis was induced by cystine deprivation and/or erastin treatment. The GO OFs possessed stronger resistance to ferroptosis than the control OFs. Selenium, a potential ferroptosis inhibitor, protected the control OFs from ferroptosis. Both transcriptomic and proteomic analyses indicated glycolytic shift in the GO OFs. Metabolic profiling, PDK2 quantification, and oxygen consumption assay confirmed enhanced glycolysis in the GO OFs. Inhibition of glycolysis by PDK2 knockdown and dichloroacetic acid (DCA) promoted ferroptosis sensitivity in the GO OFs. The ferroptosis-sensitizing effects of DCA were also observed when the GO OFs were treated with GO-Igs. IGF1R overexpression in the GO OFs contributed to glycolysis shift. IGF1R inhibitory antibodies facilitated ferroptosis induction in the GO OFs, but the effects were less remarkable under GO-Igs treatment. These study findings establish that glycolysis facilitates ferroptosis resistance in the GO OFs, providing insights into the therapeutic role of glycolysis for GO treatment. |
Audience | Academic |
Author | Peng, Zhiyu Gan, Lu Guo, Jie Wu, Jihong Ma, Ruiqi Harrison, Andrew R Qian, Jiang |
Author_xml | – sequence: 1 givenname: Ruiqi surname: Ma fullname: Ma, Ruiqi – sequence: 2 givenname: Lu surname: Gan fullname: Gan, Lu – sequence: 3 givenname: Jie surname: Guo fullname: Guo, Jie – sequence: 4 givenname: Zhiyu surname: Peng fullname: Peng, Zhiyu – sequence: 5 givenname: Jihong surname: Wu fullname: Wu, Jihong – sequence: 6 givenname: Andrew R orcidid: 0000-0003-4005-2772 surname: Harrison fullname: Harrison, Andrew R – sequence: 7 givenname: Jiang orcidid: 0000-0002-4287-3497 surname: Qian fullname: Qian, Jiang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35303084$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU9rGzEQxUVJaZy01x7DQi65bKJ_u_LmFkLjGEJzcaE3MdbOblR2JUeSA771a-Tr9ZNUxk5DSsscBobfewzvHZED5x0S8pnRc8YZvTCDdThetD0YVot3ZMIaWZWKNeqATCjlrGwU_35IjmL8QSmTshIfyKGoBBV0Kifk69xF2z-kWMxd8sUNhuBXyUcbL4sFhB6TdX0xGzbGD5t8LTK0CAipmAV4wvjr53NxH5Y2-RWkh81H8r6DIeKn_T4m326-LK5vy7v72fz66q40ouaprFUFbSU4NExCVwuJSI1quylWBpdsyVEpaDhgCx0abIQCWSFXSFteM8bEMTnb-a6Cf1xjTHq00eAwgEO_jprXkjY5CVVn9HSH9jCgtq7zKYDZ4vpKKVVNFZNb6vwfVJ4WR2ty5p3N9zeCk_0H6-WIrV4FO0LY6JdoXx1N8DEG7P4gjOptd3rXnd53lwXyL4GxCZL1Lr9ih__JfgOwjKFJ |
CitedBy_id | crossref_primary_10_1016_j_biopha_2024_116230 crossref_primary_10_3389_fimmu_2024_1440309 crossref_primary_10_3389_fimmu_2024_1475923 crossref_primary_10_1007_s12020_024_03761_z crossref_primary_10_3390_ijms252111434 crossref_primary_10_1016_j_mito_2023_02_007 crossref_primary_10_1016_j_nbd_2022_105917 crossref_primary_10_1089_ars_2024_0585 crossref_primary_10_1515_biol_2022_0874 crossref_primary_10_1167_iovs_66_1_56 |
Cites_doi | 10.1210/endocr/bqab188 10.1007/s42000-019-00133-5 10.1016/j.cbi.2019.108894 10.1530/EJE-21-0479 10.1530/JME-20-0143 10.1097/IOP.0000000000001514 10.1210/jc.2016-1315 10.3389/fendo.2021.653627 10.3389/fendo.2020.608733 10.1016/S2213-8587(21)00056-5 10.1016/j.cmet.2020.10.011 10.1007/s40618-019-01116-4 10.1159/000494837 10.1007/s40618-021-01663-9 10.1210/en.2019-00055 10.1097/IOP.0000000000001931 10.1016/j.molcel.2018.10.042 10.1016/j.freeradbiomed.2018.09.043 10.2147/OTT.S254995 10.1210/jc.2018-01626 10.1056/NEJMoa1012985 10.1038/s41422-020-00441-1 10.1159/000511538 10.1210/clinem/dgab154 10.1038/s41577-020-00478-8 10.1155/2020/9210572 10.1002/cbf.3632 10.3389/fendo.2020.608428 10.1146/annurev-biochem-061516-045037 10.1210/clinem/dgab256 10.1038/s41580-020-00324-8 10.1210/jc.2017-01736 10.1007/s00417-021-05339-1 10.1038/s41574-019-0305-4 10.1016/j.cmet.2017.10.005 10.1055/a-0658-7889 10.1167/iovs.19-27376 10.1084/jem.20210518 10.1146/annurev-cellbio-092910-154237 10.3390/cells10020383 10.1038/s41422-019-0164-5 10.1507/endocrj.EJ19-0521 10.1016/j.cell.2013.12.010 10.1056/NEJMoa1910434 10.1111/ceo.13899 10.1089/thy.2018.0089 10.1210/clinem/dgab035 10.1167/iovs.18-26268 |
ContentType | Journal Article |
Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. COPYRIGHT 2022 Oxford University Press |
Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. – notice: COPYRIGHT 2022 Oxford University Press |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1210/clinem/dgac163 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 2003 |
ExternalDocumentID | A777587146 35303084 10_1210_clinem_dgac163 |
Genre | Journal Article |
GeographicLocations | United States China |
GeographicLocations_xml | – name: China – name: United States |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 82171099 – fundername: Natural Science Foundation of Shanghai grantid: 20ZR1409500 |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 7X7 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL AAYXX ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ABXZS ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADNBA ADQBN ADRTK ADVEK AELWJ AEMDU AEMQT AENEX AENZO AEOTA AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AFYAG AGINJ AGORE AGQXC AGUTN AHGBF AHMBA AHMMS AJBYB AJEEA ALMA_UNASSIGNED_HOLDINGS ALXQX APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CDBKE CITATION CS3 D-I DAKXR DIK E3Z EBS EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HZ~ H~9 IAO IHR INH ITC KBUDW KOP KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NU- O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PQQKQ PROAC REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 AGKRT KQ8 NPM 7X8 |
ID | FETCH-LOGICAL-c362t-675ad532a914af634ee0c7df8e5ceb1b2e77a92aedafece937a45e27e0d261113 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Fri Jul 11 14:31:00 EDT 2025 Tue Jun 17 22:23:57 EDT 2025 Tue Jun 10 21:20:20 EDT 2025 Wed Feb 19 02:25:52 EST 2025 Thu Apr 24 23:10:48 EDT 2025 Tue Jul 01 01:11:07 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | cystine deprivation ferroptosis Graves’ orbitopathy glycolysis orbital fibroblast |
Language | English |
License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c362t-675ad532a914af634ee0c7df8e5ceb1b2e77a92aedafece937a45e27e0d261113 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4005-2772 0000-0002-4287-3497 |
PMID | 35303084 |
PQID | 2640994576 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2640994576 gale_infotracmisc_A777587146 gale_infotracacademiconefile_A777587146 pubmed_primary_35303084 crossref_primary_10_1210_clinem_dgac163 crossref_citationtrail_10_1210_clinem_dgac163 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-06-16 |
PublicationDateYYYYMMDD | 2022-06-16 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-16 day: 16 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2022 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Fang (2022061616024386000_CIT0044) 2019; 104 Negro (2022061616024386000_CIT0018) 2019; 8 Ma (2022061616024386000_CIT0025) 2019; 60 Yuksel (2022061616024386000_CIT0010) 2020; 36 Kahaly (2022061616024386000_CIT0048) 2017; 102 Tang (2022061616024386000_CIT0034) 2021; 31 Kahaly (2022061616024386000_CIT0024) 2021; 9 Wang (2022061616024386000_CIT0039) 2021; 106 Rotondo Dottore (2022061616024386000_CIT0006) 2021; 106 Lunt (2022061616024386000_CIT0036) 2011; 27 Chen (2022061616024386000_CIT0029) 2021; 218 Neumann (2022061616024386000_CIT0045) 2020; 9 Hirschhorn (2022061616024386000_CIT0027) 2019; 133 Yang (2022061616024386000_CIT0033) 2014; 156 Taylor (2022061616024386000_CIT0001) 2020; 16 Zheng (2022061616024386000_CIT0031) 2020; 32 Ma (2022061616024386000_CIT0016) 2020; 65 Temiz Karadag (2022061616024386000_CIT0038) 2021; 39 Sies (2022061616024386000_CIT0008) 2017; 86 Weber (2022061616024386000_CIT0037) 2021; 259 Ko (2022061616024386000_CIT0009) 2020; 67 Douglas (2022061616024386000_CIT0021) 2020; 382 Lanzolla (2022061616024386000_CIT0004) 2020; 11 Marcocci (2022061616024386000_CIT0020) 2011; 364 Ekronarongchai (2022061616024386000_CIT0007) 2021; 31 Janssen (2022061616024386000_CIT0023) 2021; 10 Muri (2022061616024386000_CIT0013) 2021; 21 Gao (2022061616024386000_CIT0014) 2019; 73 Jiang (2022061616024386000_CIT0028) 2021; 22 Tang (2022061616024386000_CIT0030) 2019; 29 Bartalena (2022061616024386000_CIT0002) 2021; 185 Jain (2022061616024386000_CIT0022) 2021; 49 Choudhry (2022061616024386000_CIT0035) 2018; 27 Kim (2022061616024386000_CIT0050) 2021; 37 Neag (2022061616024386000_CIT0003) 2022; 45 Stockwell (2022061616024386000_CIT0032) 2017; 171 Marcus-Samuels (2022061616024386000_CIT0046) 2018; 28 Lee (2022061616024386000_CIT0011) 2019; 60 Hai (2022061616024386000_CIT0005) 2020; 43 Shi (2022061616024386000_CIT0041) 2021; 106 Tian (2022061616024386000_CIT0017) 2020; 2020 Zhang (2022061616024386000_CIT0040) 2021; 162 Li (2022061616024386000_CIT0012) 2020; 315 Krieger (2022061616024386000_CIT0043) 2019; 160 Marinò (2022061616024386000_CIT0049) 2018; 50 Zhao (2022061616024386000_CIT0015) 2020; 13 Smith (2022061616024386000_CIT0042) 2021; 12 Lanzolla (2022061616024386000_CIT0047) 2021; 11 Krieger (2022061616024386000_CIT0026) 2016; 101 Bednarczuk (2022061616024386000_CIT0019) 2020; 19 |
References_xml | – volume: 162 start-page: bqab188 issue: 12 year: 2021 ident: 2022061616024386000_CIT0040 article-title: The role of mitochondria-linked fatty-acid uptake-driven adipogenesis in Graves orbitopathy publication-title: Endocrinology. doi: 10.1210/endocr/bqab188 – volume: 19 start-page: 31 issue: 1 year: 2020 ident: 2022061616024386000_CIT0019 article-title: Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy publication-title: Hormones (Athens). doi: 10.1007/s42000-019-00133-5 – volume: 315 start-page: 108894 year: 2020 ident: 2022061616024386000_CIT0012 article-title: Polydatin attenuates orbital oxidative stress in Graves’ orbitopathy through the NRF2 pathway publication-title: Chem Biol Interact. doi: 10.1016/j.cbi.2019.108894 – volume: 185 start-page: G43 issue: 4 year: 2021 ident: 2022061616024386000_CIT0002 article-title: The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy publication-title: Eur J Endocrinol. doi: 10.1530/EJE-21-0479 – volume: 65 start-page: 163 issue: 4 year: 2020 ident: 2022061616024386000_CIT0016 article-title: PDK2-enhanced glycolysis promotes fibroblast proliferation in thyroid-associated ophthalmopathy publication-title: J Mol Endocrinol. doi: 10.1530/JME-20-0143 – volume: 36 start-page: 172 issue: 2 year: 2020 ident: 2022061616024386000_CIT0010 article-title: The effect of smoking on mitochondrial biogenesis in patients with Graves ophthalmopathy publication-title: Ophthalmic Plast Reconstr Surg. doi: 10.1097/IOP.0000000000001514 – volume: 101 start-page: 2340 issue: 6 year: 2016 ident: 2022061616024386000_CIT0026 article-title: TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2016-1315 – volume: 12 start-page: 653627 year: 2021 ident: 2022061616024386000_CIT0042 article-title: Insulin-like growth factor pathway and the thyroid publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2021.653627 – volume: 11 start-page: 608733 year: 2020 ident: 2022061616024386000_CIT0004 article-title: Antioxidant therapy in Graves’ orbitopathy publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2020.608733 – volume: 9 start-page: 360 issue: 6 year: 2021 ident: 2022061616024386000_CIT0024 article-title: Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(21)00056-5 – volume: 32 start-page: 920 issue: 6 year: 2020 ident: 2022061616024386000_CIT0031 article-title: The metabolic underpinnings of ferroptosis publication-title: Cell Metab. doi: 10.1016/j.cmet.2020.10.011 – volume: 43 start-page: 123 issue: 2 year: 2020 ident: 2022061616024386000_CIT0005 article-title: Immunohistochemical analysis of human orbital tissue in Graves’ orbitopathy publication-title: J Endocrinol Invest. doi: 10.1007/s40618-019-01116-4 – volume: 8 start-page: 7 issue: 1 year: 2019 ident: 2022061616024386000_CIT0018 article-title: A 2018 European Thyroid Association survey on the use of selenium supplementation in Graves’ hyperthyroidism and Graves’ orbitopathy publication-title: Eur Thyroid J. doi: 10.1159/000494837 – volume: 45 start-page: 235 issue: 2 year: 2022 ident: 2022061616024386000_CIT0003 article-title: 2021 update on thyroid-associated ophthalmopathy publication-title: J Endocrinol Invest. doi: 10.1007/s40618-021-01663-9 – volume: 160 start-page: 1468 issue: 6 year: 2019 ident: 2022061616024386000_CIT0043 article-title: Arrestin-β-1 Physically scaffolds TSH and IGF1 receptors to enable crosstalk publication-title: Endocrinology. doi: 10.1210/en.2019-00055 – volume: 37 start-page: 476 issue: 5 year: 2021 ident: 2022061616024386000_CIT0050 article-title: Anti-inflammatory and antioxidant effects of selenium on orbital fibroblasts of patients with Graves ophthalmopathy publication-title: Ophthalmic Plast Reconstr Surg. doi: 10.1097/IOP.0000000000001931 – volume: 31 start-page: 1566 issue: 10 year: 2021 ident: 2022061616024386000_CIT0007 article-title: Histone deacetylase 4 controls extracellular matrix production in orbital fibroblasts from Graves’ ophthalmopathy patients publication-title: Thyroid. – volume: 73 start-page: 354 issue: 2 year: 2019 ident: 2022061616024386000_CIT0014 article-title: Role of mitochondria in ferroptosis publication-title: Mol Cell. doi: 10.1016/j.molcel.2018.10.042 – volume: 171 start-page: 273 issue: 2 year: 2017 ident: 2022061616024386000_CIT0032 article-title: Ferroptosis: a regulated cell death nexus linking metabolism publication-title: Redox Biol Dis Cell. – volume: 133 start-page: 130 year: 2019 ident: 2022061616024386000_CIT0027 article-title: The development of the concept of ferroptosis publication-title: Free Radic Biol Med. doi: 10.1016/j.freeradbiomed.2018.09.043 – volume: 13 start-page: 5429 year: 2020 ident: 2022061616024386000_CIT0015 article-title: The role of erastin in ferroptosis and its prospects in cancer therapy publication-title: Onco Targets Ther. doi: 10.2147/OTT.S254995 – volume: 104 start-page: 1697 issue: 5 year: 2019 ident: 2022061616024386000_CIT0044 article-title: Insights into local orbital immunity: evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-01626 – volume: 364 start-page: 1920 issue: 20 year: 2011 ident: 2022061616024386000_CIT0020 article-title: Selenium and the course of mild Graves’ orbitopathy publication-title: N Engl J Med. doi: 10.1056/NEJMoa1012985 – volume: 31 start-page: 107 issue: 2 year: 2021 ident: 2022061616024386000_CIT0034 article-title: Ferroptosis: molecular mechanisms and health implications publication-title: Cell Res. doi: 10.1038/s41422-020-00441-1 – volume: 9 start-page: 59 year: 2020 ident: 2022061616024386000_CIT0045 article-title: Targeting TSH and IGF-1 receptors to treat thyroid eye disease publication-title: Eur Thyroid J. doi: 10.1159/000511538 – volume: 106 start-page: e3125 issue: 8 year: 2021 ident: 2022061616024386000_CIT0041 article-title: IL-38 exerts anti-inflammatory and antifibrotic effects in thyroid-associated ophthalmopathy publication-title: J Clin Endocrinol Metab. doi: 10.1210/clinem/dgab154 – volume: 21 start-page: 363 issue: 6 year: 2021 ident: 2022061616024386000_CIT0013 article-title: Redox regulation of immunometabolism publication-title: Nat Rev Immunol. doi: 10.1038/s41577-020-00478-8 – volume: 2020 start-page: 9210572 year: 2020 ident: 2022061616024386000_CIT0017 article-title: Selenium supplementation may decrease thyroid peroxidase antibody titer via reducing oxidative stress in euthyroid patients with autoimmune thyroiditis publication-title: Int J Endocrinol. doi: 10.1155/2020/9210572 – volume: 39 start-page: 658 issue: 5 year: 2021 ident: 2022061616024386000_CIT0038 article-title: Proteomic analysis of thyroid tissue reveals enhanced catabolic activity in Graves’ disease compared to toxic multinodular goitre publication-title: Cell Biochem Funct doi: 10.1002/cbf.3632 – volume: 11 start-page: 608428 year: 2021 ident: 2022061616024386000_CIT0047 article-title: Selenium in the treatment of Graves’ hyperthyroidism and eye disease publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2020.608428 – volume: 86 start-page: 715 year: 2017 ident: 2022061616024386000_CIT0008 article-title: Oxidative stress publication-title: Annu Rev Biochem. doi: 10.1146/annurev-biochem-061516-045037 – volume: 106 start-page: e2866 issue: 8 year: 2021 ident: 2022061616024386000_CIT0039 article-title: LncRNA LPAL2/miR-1287-5p/EGFR axis modulates TED-derived orbital fibroblast activation through cell adhesion factors publication-title: J Clin Endocrinol Metab. doi: 10.1210/clinem/dgab256 – volume: 22 start-page: 266 issue: 4 year: 2021 ident: 2022061616024386000_CIT0028 article-title: Ferroptosis: mechanisms, biology and role in disease publication-title: Nat Rev Mol Cell Biol. doi: 10.1038/s41580-020-00324-8 – volume: 102 start-page: 4333 issue: 11 year: 2017 ident: 2022061616024386000_CIT0048 article-title: Double-blind, placebo-controlled, randomized trial of selenium in Graves hyperthyroidism publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2017-01736 – volume: 259 start-page: 3107 issue: 10 year: 2021 ident: 2022061616024386000_CIT0037 article-title: 18 F-FDG-PET/MRI in patients with Graves’ orbitopathy publication-title: Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-021-05339-1 – volume: 16 start-page: 104 issue: 2 year: 2020 ident: 2022061616024386000_CIT0001 article-title: New insights into the pathogenesis and nonsurgical management of Graves orbitopathy publication-title: Nat Rev Endocrinol. doi: 10.1038/s41574-019-0305-4 – volume: 27 start-page: 281 issue: 2 year: 2018 ident: 2022061616024386000_CIT0035 article-title: Advances in hypoxia-inducible factor biology publication-title: Cell Metab. doi: 10.1016/j.cmet.2017.10.005 – volume: 50 start-page: 887 issue: 12 year: 2018 ident: 2022061616024386000_CIT0049 article-title: Mechanistic pathways of selenium in the treatment of Graves’ disease and Graves’ orbitopathy publication-title: Horm Metab Res. doi: 10.1055/a-0658-7889 – volume: 60 start-page: 4129 issue: 13 year: 2019 ident: 2022061616024386000_CIT0011 article-title: Therapeutic effect of Curcumin, a plant polyphenol extracted from Curcuma longae, in fibroblasts from patients with Graves’ orbitopathy publication-title: Invest Ophthalmol Vis Sci. doi: 10.1167/iovs.19-27376 – volume: 218 start-page: e20210518 issue: 6 year: 2021 ident: 2022061616024386000_CIT0029 article-title: Ferroptosis in infection, inflammation, and immunity publication-title: J Exp Med. doi: 10.1084/jem.20210518 – volume: 27 start-page: 441 year: 2011 ident: 2022061616024386000_CIT0036 article-title: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation publication-title: Annu Rev Cell Dev Biol. doi: 10.1146/annurev-cellbio-092910-154237 – volume: 10 start-page: 383 issue: 2 year: 2021 ident: 2022061616024386000_CIT0023 article-title: Lessons learned from targeting IGF-I receptor in thyroid-associated ophthalmopathy publication-title: Cells doi: 10.3390/cells10020383 – volume: 29 start-page: 347 issue: 5 year: 2019 ident: 2022061616024386000_CIT0030 article-title: The molecular machinery of regulated cell death publication-title: Cell Res. doi: 10.1038/s41422-019-0164-5 – volume: 67 start-page: 439 issue: 4 year: 2020 ident: 2022061616024386000_CIT0009 article-title: Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves’ orbitopathy publication-title: Endocr J. doi: 10.1507/endocrj.EJ19-0521 – volume: 156 start-page: 317 issue: 1-2 year: 2014 ident: 2022061616024386000_CIT0033 article-title: Regulation of ferroptotic cancer cell death by GPX4 publication-title: Cell. doi: 10.1016/j.cell.2013.12.010 – volume: 382 start-page: 341 issue: 4 year: 2020 ident: 2022061616024386000_CIT0021 article-title: Teprotumumab for the treatment of active thyroid eye disease publication-title: N Engl J Med. doi: 10.1056/NEJMoa1910434 – volume: 49 start-page: 203 issue: 2 year: 2021 ident: 2022061616024386000_CIT0022 article-title: Thyroid eye disease: redefining its management-a review publication-title: Clin Exp Ophthalmol. doi: 10.1111/ceo.13899 – volume: 28 start-page: 650 issue: 5 year: 2018 ident: 2022061616024386000_CIT0046 article-title: Evidence that Graves’ ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors publication-title: Thyroid. doi: 10.1089/thy.2018.0089 – volume: 106 start-page: e2176 issue: 5 year: 2021 ident: 2022061616024386000_CIT0006 article-title: Genetic profiling of orbital fibroblasts from patients with Graves’ orbitopathy publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgab035 – volume: 60 start-page: 1431 issue: 5 year: 2019 ident: 2022061616024386000_CIT0025 article-title: PH20 inhibits TGFβ1-induced differentiation of perimysial orbital fibroblasts via hyaluronan-CD44 pathway in thyroid-associated ophthalmopathy publication-title: Invest Ophthalmol Vis Sci. doi: 10.1167/iovs.18-26268 |
SSID | ssj0014453 |
Score | 2.4696035 |
Snippet | Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death resulting from... Context: Oxidative stress plays an indispensable role in pathogenesis of Graves' orbitopathy (GO). Ferroptosis is a newly discovered form of cell death... |
SourceID | proquest gale pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1994 |
SubjectTerms | Antibodies Cell death Cysteine Cystine Glucose metabolism Glutamate International economic relations Lipid peroxidation Scientific equipment and supplies industry Selenium Thyrotropin Viral antibodies |
Title | Insights Into Ferroptosis: Targeting Glycolysis to Treat Graves’ Orbitopathy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35303084 https://www.proquest.com/docview/2640994576 |
Volume | 107 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuiH-6LChISBxWgSZx4obbCtFdkHa5dKWKS-Q4E6hUkqVJDrsn3oAzr8eTMGO7bloVaeESRY5jOZkv4_mc-WHs5RibSwWxH0rBfS5F6csxcH8UF2WQFioYpxQ7fHqWnJzzj7N4Nhj87HktdW3-Wl3tjCv5H6liG8qVomT_QbJuUGzAc5QvHlHCeLyWjD9UDXHrhvb16sMJLJf1RVs3c-3mNtU-3np_aXGJ4tapR6jQi94UOKayQ83K1SE9_LTM8dum-sQb_3kJRb3kEi6OEqqiRn1TrTM4fYMW8bRYZSTUm9xaft38-9x5-dhIh841dObPzxzWOtpon89f55ddf08C6SwV80n6epYcP4QulI6rjFGtKY99ERhvXKd7TclbCzLR06SUs7i3KpMP3U6Nj5QVxUSPD_gBTYovUgVWZW4k195a9JwrIpEgHCMzI2T2_hvsZoi8g0piHM-czxCST5vW1D6ezQJKYVDm_jf2_g0rZ3ut32Iw2pKZ3mV3LAXxjgye7rEBVPfZrVPrZPGAna1g5RGsvB6s3noOVN4aVB520qDyDKh-__jl9eD0kJ1P3k_fnfi27Iav0JppfaSQsoijUKYBl2UScYCREkU5hljhyp6HIIRMQwmFLEEB2reSxxAKGBVIx4MgesT2qrqCJ8wLU1nkkKNVHyccVUCaiEjFJar9KFdcjIfMX72mTNmc9FQaZZHtFsuQvXL9L0w2lr_3pLeeEVZwRCVttAnOixKeZUdCIFMWaCcM2cFGT1SvauPyi5XcMrpEPokV1F2TIZVAesWRsA_ZYyNQN6kojigRFN-_9oSfstvrL-mA7bXLDp6hvdvmzzUG_wBVWbDY |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Insights+Into+Ferroptosis%3A+Targeting+Glycolysis+to+Treat+Graves%E2%80%99+Orbitopathy&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Ma%2C+Ruiqi&rft.au=Gan%2C+Lu&rft.au=Guo%2C+Jie&rft.au=Peng%2C+Zhiyu&rft.date=2022-06-16&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=107&rft.issue=7&rft.spage=1994&rft.epage=2003&rft_id=info:doi/10.1210%2Fclinem%2Fdgac163&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_clinem_dgac163 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |